Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile
General Stock Board Listed Company Profile
Code:
Industry:
Local/Foreign Company:
6576 Foresee
中文
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
Benjamin Chien Lawrence Gan Max Chan (02)77500188 9F-2., No.19-3, Sanchong Rd., Nangang Dist.,Taipei City 115, Taiwan (R.O.C.) 2018/06/29
Industry Main Business
Biotechnology and Medical Care
逸達生物科技股份有限公司是一家新興生物製藥公司。本公司專注於研發緩釋藥物輸送平臺(Stabilized Injectable Formulation , SIF),核心技術可應用開發新劑型配方之小分子、胜月太及蛋白質藥物,本公司目前開發方向聚焦505(b)(2)NDA申請途徑之新劑型新藥,主要研發治療抗癌及慢性疾病之利基市場藥物,為台灣專注於全球市場之新劑型藥物研發之新興廠商。 此外,逸達亦透過合理性藥物設計技術(Rational Drug Design)自行研發合成新化合物(NCE)跨入新藥開發之領域,除開發新劑型新藥所挹注穩定收益外,藉由開發新藥提昇本公司的研發能量,以成為具國際領導地位之研發型新藥廠商。
 
Market Information ( 2019/12/10 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
margin
balance
(1,000shr.)
Short
margin
balance
(1,000shr.)
65.183 60.70  60.00  60.40  0.20  57 0.06 N/A N/A
Trading method Fun
purchase
price or
securities
pneeded
on T day
Announcement of Irregularity
(2019/12/10)
TPEx measures
adopted
(2019/12/10)
With warrants Can be shorted or margined? Detail
Normal N N N N N Today History
 
Financial Reports
Cash Flows Items
Amount
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Balance
Sheets
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Profit
Other comprehensive income
Comprehensive income
Basic earnings per share
* Auditor's report on latest financial statements: auditor's report:
* More detail:MOPS
* Foreign issuers’ information is disclosed in consolidated statements.